Oncimmune EarlyCDT lung blood test data presented to CHEST Annual Meeting 2020

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has noted that recently published data from two clinical studies using Oncimmune’s EarlyCDT® Lung blood test, which is marketed in the US by Biodesix Inc. as Nodify CDTTM, confirmed both previously published performance, and the utility of combining Nodify CDT and Nodify XL2® tests to enhance diagnostic performance. Furthermore, these studies were recently presented at the American College of Chest Physicians (CHEST) annual meeting 2020.

The first paper (‘Abstract #A1464/Poster #P1319: ‘Identification of Likely Malignant Indeterminate Pulmonary Nodules by Analysis of Autoantibodies Against Lung Cancer-Associated Antigens‘) assessed the performance of the EarlyCDT Lung blood test in PANOPTIC clinical trial samples to further validate the clinical utility of the test in patients with incidentally identified lung nodules when correlated with clinical outcomes (average 2 years follow-up). The reported specificity 93% (95% confidence interval (CI) 86-97%) and positive predictive value (PPV) 74% (CI 57-85%) correlates with previous publications of the EarlyCDT Lung blood test.

The second paper (‘Abstract #A1476/Poster #P1324: ‘Use of Two Blood-Based Biomarker Tests in Series to Reclassify Risk of Indeterminate Pulmonary Nodules’) evaluated the utility of combining Nodify CDT and Nodify XL2 tests in series. This combination strategy is aligned with the marketing strategy of both products by Biodesix in the US. 32% of the IPNs in the low-moderate risk category were reclassified into either the high-risk category by Nodify CDT or the very low risk category by Nodify XL2. Therefore, this testing strategy could have reclassified 3 malignant nodules into earlier biopsy, and 6 benign nodules that unfortunately underwent unnecessary invasive procedures. By shifting 32% of patients into risk groups with different guideline recommended diagnostic plans, the combined testing strategy would have reduced delays in diagnosis of malignant nodules and helped reduce unnecessary procedures on benign nodules.

Oncimmune’s EarlyCDT Lung blood test is marketed in the US under Biodesix’s Nodify Lung brand as Nodify CDT. The test will assist physicians to identify patients with lung nodules at high risk of lung cancer. This test partners with Biodesix’s existing Nodify XL2 test which is designed to help identify lung nodules with a very low risk of cancer. Both tests will be offered together as the Nodify LungTM Nodule Risk Assessment strategy, giving physicians the ability to order both tests from a single blood draw.

Biodesix has a direct US national sales force who sell direct into pulmonologists and corporately into national hospital systems.

Dr Adam M Hill, CEO of Oncimmune commented: “Whilst the EarlyCDT Lung blood test is underpinned by substantive evidence of its utility in IPN patients and reduction in unnecessary invasive procedures, I welcome this independent validation of the panel with the important PANOPTIC sample set, and confirmation of the utility of a combined rule-in and rule-out strategy in the US nodule clinic setting.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn

    More articles like this

    Oncimmune Holdings report two further ImmunoINSIGHTS contracts signed

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer

    Oncimmune signs new commercial follow-on contract 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous

    Oncimmune signs go-to-market partnership with Synexa Life Sciences

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science, focused on delivering a range of biomarker

    Oncimmune signs new commercial contract with Verily Life Sciences 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial contract with Verily Life Sciences LLC, an Alphabet company (parent company to Google), focusing on the autoantibody profiling of patients

    Oncimmune Holdings Notice of half year results

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has stated today that it will be announcing its half year results for the six months ended 30 November 2021 on 28 February 2022. ImmunoINSIGHTS Service Business Oncimmune

    Oncimmune achieves FY2021 revenue of £3.7 million

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its audited results for the year ended 31 May 2021 and provides an update on recent progress and the outlook for the current financial year.

    Oncimmune to evaluate the profile of patients using ImmunoINSIGHTS

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The